A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

NCT00942578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

NIH

Sponsor class

Conditions

Metastatic Prostate Cancer

Interventions

DRUG: Bevacizumab
DRUG: Lenalidomide
DRUG: Docetaxel
DRUG: Prednisone

Sponsor

National Cancer Institute (NCI)